Lyra Therapeutics, Inc. Common Stock (LYRA)
Lyra Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for chronic nasal and sinus conditions. The company leverages a proprietary delivery platform to address unmet medical needs in ENT (ear, nose, and throat) disorders, aiming to provide minimally invasive treatments with long-lasting effects.
Company News
Lyra Therapeutics reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210, a treatment for chronic rhinosinusitis. The trial met its primary and key secondary endpoints, demonstrating statistically significant improvements in symptoms compared to sham control.
Analysts' ratings for Lyra Therapeutics (NASDAQ:LYRA) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat...
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
All three small-cap biotech/biopharma stocks have attractive risk/reward profiles and potential catalysts on the horizon. Click here for the complete stock list.